Medpace Holdings, Inc. $MEDP Stock Sold by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 80.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 51,031 shares of the company’s stock after selling 216,144 shares during the period. Mawer Investment Management Ltd.’s holdings in Medpace were worth $31,853,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Medpace during the second quarter valued at approximately $1,323,047,000. Aberdeen Group plc lifted its holdings in shares of Medpace by 5,119.5% during the third quarter. Aberdeen Group plc now owns 2,231,252 shares of the company’s stock valued at $1,392,703,000 after purchasing an additional 2,188,504 shares during the last quarter. Madison Asset Management LLC purchased a new position in shares of Medpace during the second quarter valued at approximately $128,956,000. Bank of America Corp DE purchased a new position in shares of Medpace during the second quarter valued at approximately $116,891,000. Finally, American Capital Management Inc. bought a new stake in shares of Medpace in the 2nd quarter worth approximately $111,329,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In related news, General Counsel Stephen Ewald sold 1,245 shares of Medpace stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $690.00, for a total value of $859,050.00. Following the completion of the sale, the general counsel directly owned 19,098 shares in the company, valued at approximately $13,177,620. This trade represents a 6.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August Troendle sold 21,966 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the transaction, the chief executive officer directly owned 338,225 shares of the company’s stock, valued at approximately $211,549,590.75. This trade represents a 6.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 306,539 shares of company stock worth $191,774,429. 20.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. BMO Capital Markets upped their price target on Medpace from $600.00 to $670.00 and gave the stock a “market perform” rating in a research note on Monday, October 26th. Mizuho set a $730.00 price objective on Medpace in a research note on Friday, October 23rd. Deutsche Bank reissued a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a report on Monday, September 14th. Finally, TD Cowen increased their target price on Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a research note on Friday, October 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $649.27.

Medpace Stock Down 0.4%

Shares of Medpace stock traded down $2.90 on Friday, reaching $653.94. The company’s stock had a trading volume of 105,448 shares, compared to its average volume of 317,477. The company has a market capitalization of $18.29 billion, a price-to-earnings ratio of 36.25, a P/E/G ratio of 2.55 and a beta of 1.12. The firm’s fifty day simple moving average is $629.52 and its two-hundred day simple moving average is $533.79. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $693.97.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping the consensus estimate of $4.44 by $0.40. The firm had revenue of $716.00 million during the quarter, compared to analysts’ expectations of $714.47 million. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.86 earnings per share. As a group, research analysts predict that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.